Effects on Obesity Obesity, as a chronic recurrent disease, is known to increase the risk of developing T2MD, hypertension, dyslipidemias, CVDs, NAFLD, and other diseases, leading to a poor quality of life and increased mortality (167)
The SURPASS trial program showed A1C reductions of up to 2.3% with tirzepatide 15 mg, which is exceptional
Always consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.
In individuals with type 2 diabetes, another phase 2 clinical study demonstrated that after 12 weeks of efinopegdutide treatment, although no significant improvement in glycated hemoglobin (HbA1c) levels was observed, the effect on weight loss reached a high of 7.9%, well above the 0.7% weight reduction rate in the placebo group